Caprion

According to Caprion, the company plans to use Primity's assets to expand its existing immunology and molecular profiling business.

The company is testing a five-protein panel in longitudinal samples to see if it could help with early detection and prediction of progression in Alzheimer's.

Caprion will use its mass spec platform to measure Alzheimer's-linked proteins in the CSF of more than 200 patients and controls over three or more years.

The company expects its purchase of ImmuneHealth's immune monitoring laboratory will help it win business for clinical work requiring fresh sample analysis.

Caprion said it will use the lab to expand its immune monitoring offering and strengthen its business partnerships and research collaborations in Europe.

Under new ownership after being acquired by GHO Capital, the company will consider expanding its business through acquisitions and moving into new geographies.

GHO, a London-based investment firm, purchased the company for an undisclosed amount from Chicago Growth Partners, Caprion's majority shareholder since 2012.

The study, which looked at markers of immune senescence in older patients, suggests the platform could be useful in diagnostic and companion diagnostic work. 

The company hopes to launch the test sometime this year after completing CLIA certification of its clinical laboratory and securing reimbursement.

The agreement gives Caprion, which did significant development work on the test, exclusive rights to market and commercialize Xpresys Lung inCanada.

Pages

John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.

Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.

Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.

In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.